First-Line Combination Treatment with Low-Dose Bipolar Drugs for ABCB1-Overexpressing Drug-Resistant Cancer Populations
Abstract
:1. Introduction
2. Candidate Bipolar Drugs for First-Line Combination Treatments
2.1. Aripiprazole
2.2. Fluphenazine
2.3. Thioridazine
2.4. Trifluoperazine
2.5. Pimozide
2.6. Quetiapine
2.7. Loxapine and Iloperidone
3. Conclusions
4. Future Prospects
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
References
- Al-Lazikani, B.; Banerji, U.; Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 2012, 30, 679–692. [Google Scholar] [CrossRef] [PubMed]
- Brown, R.; Curry, E.; Magnani, L.; Wilhelm-Benartzi, C.S.; Borley, J. Poised epigenetic states and acquired drug resistance in cancer. Nat. Rev. Cancer 2014, 14, 747–753. [Google Scholar] [CrossRef] [PubMed]
- Shaikh, N.; McClelland, S.E. Diversity in chromosome numbers promotes resistance to chemotherapeutics. Dev. Cell 2021, 56, 2399–2400. [Google Scholar] [CrossRef]
- Kathawala, R.J.; Wang, Y.J.; Ashby, C.R., Jr.; Chen, Z.S. Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chin. J. Cancer 2014, 33, 223–230. [Google Scholar] [CrossRef] [PubMed]
- Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219–234. [Google Scholar] [CrossRef]
- Yang, K.; Wu, J.; Li, X. Recent advances in the research of P-glycoprotein inhibitors. Biosci. Trends 2008, 2, 137–146. [Google Scholar]
- Chen, Z.; Shi, T.; Zhang, L.; Zhu, P.; Deng, M.; Huang, C.; Hu, T.; Jiang, L.; Li, J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016, 370, 153–164. [Google Scholar] [CrossRef]
- Cho, Y.; Kim, Y.K. Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance. Front. Oncol. 2020, 10, 764. [Google Scholar] [CrossRef]
- Robinson, K.; Tiriveedhi, V. Perplexing Role of P-Glycoprotein in Tumor Microenvironment. Front. Oncol. 2020, 10, 265. [Google Scholar] [CrossRef] [PubMed]
- Seelig, A. P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers. Front. Oncol. 2020, 10, 576559. [Google Scholar] [CrossRef]
- Yoon, S.; Kim, H.S. Drug Repositioning With an Anticancer Effect: Contributions to Reduced Cancer Incidence in Susceptible Individuals. In Vivo 2021, 35, 3039–3044. [Google Scholar] [CrossRef]
- Yoon, S.; Wang, X.; Vongpunsawad, S.; Tromp, G.; Kuivaniemi, H. Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer. Front. Oncol. 2021, 11, 632657. [Google Scholar] [CrossRef]
- Yoon, S.; Kim, H.S. Contribution of Cancer-Targeting Drugs toward Faster Clinical Application. Int. J. Mol. Sci. 2022, 23, 6445. [Google Scholar] [CrossRef] [PubMed]
- Roney, M.S.I.; Park, S.K. Antipsychotic dopamine receptor antagonists, cancer, and cancer stem cells. Arch. Pharm. Res. 2018, 41, 384–408. [Google Scholar] [CrossRef] [PubMed]
- Hendouei, N.; Saghafi, F.; Shadfar, F.; Hosseinimehr, S.J. Molecular mechanisms of anti-psychotic drugs for improvement of cancer treatment. Eur. J. Pharmacol. 2019, 856, 172402. [Google Scholar] [CrossRef]
- Huang, J.; Zhao, D.; Liu, Z.; Liu, F. Repurposing psychiatric drugs as anti-cancer agents. Cancer Lett. 2018, 419, 257–265. [Google Scholar] [CrossRef]
- Vucicevic, L.; Misirkic-Marjanovic, M.; Harhaji-Trajkovic, L.; Maric, N.; Trajkovic, V. Mechanisms and therapeutic significance of autophagy modulation by antipsychotic drugs. Cell Stress 2018, 2, 282–291. [Google Scholar] [CrossRef]
- Tuan, N.M.; Lee, C.H. Penfluridol as a Candidate of Drug Repurposing for Anticancer Agent. Molecules 2019, 24, 3659. [Google Scholar] [CrossRef]
- Antoszczak, M.; Markowska, A.; Markowska, J.; Huczynski, A. Antidepressants and Antipsychotic Agents as Repurposable Oncological Drug Candidates. Curr. Med. Chem. 2021, 28, 2137–2174. [Google Scholar] [CrossRef]
- Brown, J.S. Treatment of cancer with antipsychotic medications: Pushing the boundaries of schizophrenia and cancer. Neurosci. Biobehav. Rev. 2022, 141, 104809. [Google Scholar] [CrossRef] [PubMed]
- Jiang, C.; Lee, S.H.; Park, J.H.; Lee, J.S.; Park, J.W.; Kim, J.R.; Lee, S.H.; Kim, H.S.; Yoon, S. A Low Dose of Aripiprazole Has the Strongest Sensitization Effect Among 19 Repositioned Bipolar Drugs in P-gp-overexpressing Drug-resistant Cancer Cells. Anticancer Res. 2021, 41, 687–697. [Google Scholar] [CrossRef]
- Kim, J.Y.; Park, Y.; Lee, B.M.; Kim, H.S.; Yoon, S. P-gp Inhibition by the Anti-psychotic Drug Pimozide Increases Apoptosis, as well as Expression of pRb and pH2AX in Highly Drug-resistant KBV20C Cells. Anticancer Res. 2018, 38, 5685–5692. [Google Scholar] [CrossRef]
- Kim, J.Y.; Tae, I.H.; Lee, B.M.; Kim, H.S.; Yoon, S. Low Doses of the Anti-psychotic Drug Aripiprazole Have Strong P-gp-inhibitory Activity and Sensitize Anti-mitotic Drug-resistant Cancer Cells. Anticancer Res. 2018, 38, 5101–5108. [Google Scholar] [CrossRef] [PubMed]
- Choi, A.R.; Kim, J.H.; Yoon, S. Erratum to: Thioridazine specifically sensitizes drug-resistant cancer cells through highly increase in apoptosis and P-gp inhibition. Tumour Biol. 2015, 36, 7331. [Google Scholar] [CrossRef]
- Cheon, J.H.; Lee, B.M.; Kim, H.S.; Yoon, S. Highly Halaven-resistant KBV20C Cancer Cells Can Be Sensitized by Co-treatment with Fluphenazine. Anticancer Res. 2016, 36, 5867–5874. [Google Scholar] [CrossRef] [PubMed]
- Kim, M.S.; Yoo, B.C.; Yang, W.S.; Han, S.Y.; Jeong, D.; Song, J.M.; Kim, K.H.; Aravinthan, A.; Kim, J.H.; Kim, J.H.; et al. Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget 2018, 9, 5979–5992. [Google Scholar] [CrossRef] [PubMed]
- Badran, A.; Tul-Wahab, A.; Zafar, H.; Mohammad, N.; Imad, R.; Ashfaq Khan, M.; Baydoun, E.; Choudhary, M.I. Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro. PLoS ONE 2020, 15, e0235676. [Google Scholar] [CrossRef] [PubMed]
- Jeong, H.J.; Jung, C.W.; Kim, H.J.; Park, B.; Moon, Y.; Kim, J.Y.; Park, M.J. Aripiprazole sensitizes head and neck cancer cells to ionizing radiation by enhancing the production of reactive oxygen species. Pharmacol. Res. Perspect. 2022, 10, e00989. [Google Scholar] [CrossRef]
- Aogi, K.; Iwata, H.; Masuda, N.; Mukai, H.; Yoshida, M.; Rai, Y.; Taguchi, K.; Sasaki, Y.; Takashima, S. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann. Oncol. 2012, 23, 1441–1448. [Google Scholar] [CrossRef] [PubMed]
- Dybdal-Hargreaves, N.F.; Risinger, A.L.; Mooberry, S.L. Eribulin mesylate: Mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res 2015, 21, 2445–2452. [Google Scholar] [CrossRef] [PubMed]
- Duarte, D.; Vale, N. Antipsychotic Drug Fluphenazine against Human Cancer Cells. Biomolecules 2022, 12, 1360. [Google Scholar] [CrossRef]
- Duarte, D.; Nunes, M.; Ricardo, S.; Vale, N. Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action. Biomolecules 2022, 12, 1490. [Google Scholar] [CrossRef] [PubMed]
- Jaszczyszyn, A.; Gasiorowski, K.; Swiatek, P.; Malinka, W.; Cieslik-Boczula, K.; Petrus, J.; Czarnik-Matusewicz, B. New fluphenazine analogues as inhibitors of P-glycoprotein in human lymphocyte cultures. Contemp. Oncol. 2012, 16, 332–337. [Google Scholar] [CrossRef]
- Spengler, G.; Csonka, A.; Molnar, J.; Amaral, L. The Anticancer Activity of the Old Neuroleptic Phenothiazine-type Drug Thioridazine. Anticancer Res. 2016, 36, 5701–5706. [Google Scholar] [CrossRef]
- Zhelev, Z.; Ohba, H.; Bakalova, R.; Hadjimitova, V.; Ishikawa, M.; Shinohara, Y.; Baba, Y. Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Cancer Chemother. Pharmacol. 2004, 53, 267–275. [Google Scholar] [CrossRef]
- Spengler, G.; Molnar, J.; Viveiros, M.; Amaral, L. Thioridazine induces apoptosis of multidrug-resistant mouse lymphoma cells transfected with the human ABCB1 and inhibits the expression of P-glycoprotein. Anticancer Res. 2011, 31, 4201–4205. [Google Scholar]
- Amson, R.; Pece, S.; Lespagnol, A.; Vyas, R.; Mazzarol, G.; Tosoni, D.; Colaluca, I.; Viale, G.; Rodrigues-Ferreira, S.; Wynendaele, J.; et al. Reciprocal repression between P53 and TCTP. Nat. Med. 2011, 18, 91–99. [Google Scholar] [CrossRef] [PubMed]
- Ganapathi, R.; Grabowski, D.; Turinic, R.; Valenzuela, R. Correlation between potency of calmodulin inhibitors and effects on cellular levels and cytotoxic activity of doxorubicin (adriamycin) in resistant P388 mouse leukemia cells. Eur. J. Cancer Clin. Oncol. 1984, 20, 799–806. [Google Scholar] [CrossRef] [PubMed]
- Lin, X.; Zhang, J.; Wang, X.; Lin, G.; Chen, T. Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer. Anticancer Drugs 2020, 31, 989–996. [Google Scholar] [CrossRef] [PubMed]
- Aslostovar, L.; Boyd, A.L.; Almakadi, M.; Collins, T.J.; Leong, D.P.; Tirona, R.G.; Kim, R.B.; Julian, J.A.; Xenocostas, A.; Leber, B.; et al. A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Adv. 2018, 2, 1935–1945. [Google Scholar] [CrossRef]
- Sachlos, E.; Risueno, R.M.; Laronde, S.; Shapovalova, Z.; Lee, J.H.; Russell, J.; Malig, M.; McNicol, J.D.; Fiebig-Comyn, A.; Graham, M.; et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012, 149, 1284–1297. [Google Scholar] [CrossRef]
- Park, M.S.; Dong, S.M.; Kim, B.R.; Seo, S.H.; Kang, S.; Lee, E.J.; Lee, S.H.; Rho, S.B. Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian cancer xenografts. Oncotarget 2014, 5, 4929–4934. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Xia, L.; Lin, J.; Gong, L.; Xia, Y.; Xu, Y.; Liu, L.; Bao, J.; Zhang, C.; Chai, Y.; et al. Thioridazine combined with carboplatin results in synergistic inhibition of triple negative breast cancer by targeting cancer stem cells. Transl. Oncol. 2022, 26, 101549. [Google Scholar] [CrossRef] [PubMed]
- Ramu, A.; Spanier, R.; Rahamimoff, H.; Fuks, Z. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells. Br. J. Cancer 1984, 50, 501–507. [Google Scholar] [CrossRef] [PubMed]
- Ke, X.Y.; Lin Ng, V.W.; Gao, S.J.; Tong, Y.W.; Hedrick, J.L.; Yang, Y.Y. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials 2014, 35, 1096–1108. [Google Scholar] [CrossRef]
- Limniatis, G.; Georges, E. The phenothiazine, trifluoperazine, is selectively lethal to ABCB1-expressing multidrug resistant cells. Biochem. Biophys. Res. Commun. 2021, 570, 148–153. [Google Scholar] [CrossRef] [PubMed]
- Datta, S.; Sears, T.; Cortopassi, G.; Woolard, K.; Angelastro, J.M. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells. Biomed. Pharmacother. 2021, 133, 111058. [Google Scholar] [CrossRef]
- Xia, Y.; Xu, F.; Xiong, M.; Yang, H.; Lin, W.; Xie, Y.; Xi, H.; Xue, Q.; Ye, T.; Yu, L. Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux. Pharmacol. Res. 2021, 163, 105295. [Google Scholar] [CrossRef]
- Chen, X.; Luo, X.; Cheng, Y. Trifluoperazine prevents FOXO1 nuclear excretion and reverses doxorubicin-resistance in the SHG44/DOX drug-resistant glioma cell line. Int. J. Mol. Med. 2018, 42, 3300–3308. [Google Scholar] [CrossRef] [PubMed]
- Kuo, K.L.; Liu, S.H.; Lin, W.C.; Hsu, F.S.; Chow, P.M.; Chang, Y.W.; Yang, S.P.; Shi, C.S.; Hsu, C.H.; Liao, S.M.; et al. Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study. Int. J. Mol. Sci. 2019, 20, 3218. [Google Scholar] [CrossRef] [PubMed]
- Molins, E.A.G.; Jusko, W.J. Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells. AAPS J. 2018, 20, 80. [Google Scholar] [CrossRef]
- Shaw, V.; Srivastava, S.; Srivastava, S.K. Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy. Semin. Cancer Biol. 2021, 68, 75–83. [Google Scholar] [CrossRef]
- Chen, J.J.; Cai, N.; Chen, G.Z.; Jia, C.C.; Qiu, D.B.; Du, C.; Liu, W.; Yang, Y.; Long, Z.J.; Zhang, Q. The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma. Oncotarget 2017, 8, 17593–17609. [Google Scholar] [CrossRef]
- Goncalves, J.M.; Silva, C.A.B.; Rivero, E.R.C.; Cordeiro, M.M.R. Inhibition of cancer stem cells promoted by Pimozide. Clin. Exp. Pharmacol. Physiol. 2019, 46, 116–125. [Google Scholar] [CrossRef] [PubMed]
- Ranjan, A.; Kaushik, I.; Srivastava, S.K. Pimozide Suppresses the Growth of Brain Tumors by Targeting STAT3-Mediated Autophagy. Cells 2020, 9, 2141. [Google Scholar] [CrossRef] [PubMed]
- Zielke, S.; Meyer, N.; Mari, M.; Abou-El-Ardat, K.; Reggiori, F.; van Wijk, S.J.L.; Kogel, D.; Fulda, S. Loperamide, pimozide, and STF-62247 trigger autophagy-dependent cell death in glioblastoma cells. Cell Death Dis. 2018, 9, 994. [Google Scholar] [CrossRef]
- Gumus, N.; Gunduz, C.; Tezcanli Kaymaz, B. STAT5 inhibitor Pimozide as a probable therapeutic option in overcoming Ponatinib resistance in K562 leukemic cells. J. Biomol. Struct. Dyn. 2023, 41, 186–199. [Google Scholar] [CrossRef] [PubMed]
- Su, C.M.; Lin, S.S.; Wang, H.C.; Hsu, F.T.; Chung, J.G.; Hsu, L.C. The inhibitory effect and mechanism of quetiapine on tumor progression in hepatocellular carcinoma in vivo. Environ. Toxicol. 2022, 37, 92–100. [Google Scholar] [CrossRef]
- Duarte, D.; Guerreiro, I.; Vale, N. Novel Strategies for Cancer Combat: Drug Combination Using Repurposed Drugs Induces Synergistic Growth Inhibition of MCF-7 Breast and HT-29 Colon Cancer Cells. Curr. Issues Mol. Biol. 2022, 44, 4930–4949. [Google Scholar] [CrossRef]
- Wang, Y.; Huang, N.; Li, H.; Liu, S.; Chen, X.; Yu, S.; Wu, N.; Bian, X.W.; Shen, H.Y.; Li, C.; et al. Promoting oligodendroglial-oriented differentiation of glioma stem cell: A repurposing of quetiapine for the treatment of malignant glioma. Oncotarget 2017, 8, 37511–37524. [Google Scholar] [CrossRef] [PubMed]
- Broccatelli, F.; Carosati, E.; Cruciani, G.; Oprea, T.I. Transporter-mediated Efflux Influences CNS Side Effects: ABCB1, from Antitarget to Target. Mol. Inform. 2010, 29, 16–26. [Google Scholar] [CrossRef]
- Petrou, T.; Olsen, H.L.; Thrasivoulou, C.; Masters, J.R.; Ashmore, J.F.; Ahmed, A. Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium-Induced Calcium Release Mechanism. J. Pharmacol. Exp. Ther. 2017, 360, 378–387. [Google Scholar] [CrossRef]
- Chretien, B.; Lelong-Boulouard, V.; Chantepie, S.; Sassier, M.; Bertho, M.; Brazo, P.; Humbert, X.; Alexandre, J.; Fedrizzi, S.; Dolladille, C. Haematologic malignancies associated with clozapine v. all other antipsychotic agents: A pharmacovigilance study in VigiBase((R)). Psychol. Med. 2021, 51, 1459–1466. [Google Scholar] [CrossRef]
- Shukla, S.; Wu, C.P.; Ambudkar, S.V. Development of inhibitors of ATP-binding cassette drug transporters: Present status and challenges. Expert. Opin. Drug Metab. Toxicol. 2008, 4, 205–223. [Google Scholar] [CrossRef] [PubMed]
- Chaturvedi, S.; Verma, A.; Saharan, V.A. Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement. Adv. Pharm. Bull. 2020, 10, 524–541. [Google Scholar] [CrossRef] [PubMed]
- Iversen, D.B.; Andersen, N.E.; Dalgard Dunvald, A.C.; Pottegard, A.; Stage, T.B. Drug metabolism and drug transport of the 100 most prescribed oral drugs. Basic Clin. Pharmacol. Toxicol. 2022, 131, 311–324. [Google Scholar] [CrossRef] [PubMed]
Bipolar Drugs | Dose for Co-Treatment in Resistant Cancer Cells | P-gp-Inhibitory Activity |
---|---|---|
Aripiprazole | <2 μM | Extremely High |
Fluphenazine | <10 μM | Moderate |
Thioridazine | <7 μM | Moderate |
Trifluoperazine | <7 μM | Moderate |
Pimozide | <5 μM | High |
Quetiapine | <7 μM | Moderate |
Loxapine | >10 μM | Low |
Iloperidone | >10 μM | Low |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yoon, S.; Kim, H.S. First-Line Combination Treatment with Low-Dose Bipolar Drugs for ABCB1-Overexpressing Drug-Resistant Cancer Populations. Int. J. Mol. Sci. 2023, 24, 8389. https://doi.org/10.3390/ijms24098389
Yoon S, Kim HS. First-Line Combination Treatment with Low-Dose Bipolar Drugs for ABCB1-Overexpressing Drug-Resistant Cancer Populations. International Journal of Molecular Sciences. 2023; 24(9):8389. https://doi.org/10.3390/ijms24098389
Chicago/Turabian StyleYoon, Sungpil, and Hyung Sik Kim. 2023. "First-Line Combination Treatment with Low-Dose Bipolar Drugs for ABCB1-Overexpressing Drug-Resistant Cancer Populations" International Journal of Molecular Sciences 24, no. 9: 8389. https://doi.org/10.3390/ijms24098389